Quick Answer
Matinas BioPharma Holdings, Inc. reported Operating Income of -$6.96 million for fiscal year 2025.
Matinas BioPharma Holdings, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$6.96M | +71.7% |
| 2024 | -$24.59M | -3.5% |
| 2023 | -$23.77M | +3.4% |
| 2022 | -$24.59M | +0.6% |
| 2021 | -$24.73M | -2.2% |
| 2020 | -$24.21M | -27.9% |
| 2019 | -$18.92M | -29.2% |
| 2018 | -$14.65M | +11.2% |
| 2017 | -$16.50M | -99.9% |
| 2016 | -$8.26M | +16.7% |
| 2015 | -$9.91M | +5.3% |
| 2014 | -$10.46M | -181.9% |
| 2013 | -$3.71M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$1.58M | +64.0% | +14.2% |
| June 30, 2025 | -$1.84M | +68.5% | +5.6% |
| March 31, 2025 | -$1.95M | +67.0% | +55.6% |
| September 30, 2024 | -$4.38M | +28.6% | +25.0% |
| June 30, 2024 | -$5.84M | +5.2% | +1.1% |
| March 31, 2024 | -$5.90M | -5.7% | +3.8% |
| September 30, 2023 | -$6.13M | -12.3% | +0.4% |
| June 30, 2023 | -$6.16M | -3.9% | -10.3% |
- Matinas BioPharma Holdings, Inc. showed an increase of +71.7% in Operating Income compared to the prior fiscal year.
- Over the 2013–2025 period, Matinas BioPharma Holdings, Inc.’s operating income has declined by 87.5% (from -$3.71 million to -$6.96 million).
- The most recent figure is from Matinas BioPharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: